Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4856643
Max Phase: Preclinical
Molecular Formula: C19H20N2
Molecular Weight: 276.38
Molecule Type: Unknown
Associated Items:
ID: ALA4856643
Max Phase: Preclinical
Molecular Formula: C19H20N2
Molecular Weight: 276.38
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccc2[nH]c3c(c2c1)CN(Cc1ccccc1)CC3
Standard InChI: InChI=1S/C19H20N2/c1-14-7-8-18-16(11-14)17-13-21(10-9-19(17)20-18)12-15-5-3-2-4-6-15/h2-8,11,20H,9-10,12-13H2,1H3
Standard InChI Key: HLKQPYUVQYSQSX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 276.38 | Molecular Weight (Monoisotopic): 276.1626 | AlogP: 4.03 | #Rotatable Bonds: 2 |
Polar Surface Area: 19.03 | Molecular Species: NEUTRAL | HBA: 1 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.23 | CX LogP: 3.98 | CX LogD: 3.76 |
Aromatic Rings: 3 | Heavy Atoms: 21 | QED Weighted: 0.75 | Np Likeness Score: -1.18 |
1. Schwarthoff S, Tischer N, Sager H, Schätz B, Rohrbach MM, Raztsou I, Robaa D, Gaube F, Arndt HD, Winckler T.. (2021) Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors., 46 [PMID:34391122] [10.1016/j.bmc.2021.116355] |
Source(1):